<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04670666</url>
  </required_header>
  <id_info>
    <org_study_id>EMS1419 - MADALENA</org_study_id>
    <nct_id>NCT04670666</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus</brief_title>
  <official_title>National, Multicenter, Randomized, Double-blind, Triple-dummy, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Madalena association in&#xD;
      the treatment of type 2 diabetes mellitus.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in glycated hemoglobin (HbA1c) levels.</measure>
    <time_frame>120 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events recorded during the study.</measure>
    <time_frame>150 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>MADALENA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study is triple-dummy. The patient must take 3 tablets once a day, as follows:&#xD;
1 tablet Madalena association, oral;&#xD;
1 tablet empagliflozin + linagliptin association placebo, oral;&#xD;
1 tablet metformin placebo, oral.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin + empagliflozin + linagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patient must take 3 tablets once a day, as follows:&#xD;
1 tablet Madalena association placebo, oral;&#xD;
1 tablet empagliflozin + linagliptin association, oral;&#xD;
1 tablet metformin, oral.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MADALENA ASSOCIATION</intervention_name>
    <description>Madalena association coated tablet.</description>
    <arm_group_label>MADALENA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>METFORMIN</intervention_name>
    <description>Metformin 1000 mg extended-release tablet.</description>
    <arm_group_label>Metformin + empagliflozin + linagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EMPAGLIFLOZIN + LINAGLIPTIN</intervention_name>
    <description>Empagliflozin 10 mg + linagliptin 5 mg coated tablet.</description>
    <arm_group_label>Metformin + empagliflozin + linagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MADALENA ASSOCIATION PLACEBO</intervention_name>
    <description>Madalena association placebo tablet.</description>
    <arm_group_label>Metformin + empagliflozin + linagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>METFORMIN PLACEBO</intervention_name>
    <description>Metformin placebo tablet.</description>
    <arm_group_label>MADALENA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>EMPAGLIFLOZIN + LINAGLIPTIN PLACEBO</intervention_name>
    <description>Empagliflozin + linagliptin placebo tablet.</description>
    <arm_group_label>MADALENA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to confirm voluntary participation and agree to all trial purposes by signing&#xD;
             and dating the informed consent forms;&#xD;
&#xD;
          -  Participants with 18 years of age or greater;&#xD;
&#xD;
          -  Participants presenting the diagnosis of type II diabetes mellitus, and who did not&#xD;
             reach the therapeutic goals of HbA1c with previous dietary, physical exercise guidance&#xD;
             and at least 3 months with two anti-hyperglycemic agents (dual therapy);&#xD;
&#xD;
          -  HbA1c ≥ 7,5% and ≤ 10,5% and fasting blood glucose &gt; 100 mg/dL at the screening visit;&#xD;
&#xD;
          -  BMI (body mass index) &gt; 19 Kg/m2 and ≤ 45 Kg/m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any clinical and laboratory findings that, in the judgment of the investigator, may&#xD;
             interfere with the safety of research participants;&#xD;
&#xD;
          -  History of alcohol abuse or illicit drug use;&#xD;
&#xD;
          -  Participation in a clinical trial in the year prior to this study;&#xD;
&#xD;
          -  Pregnancy or risk of pregnancy and lactating patients;&#xD;
&#xD;
          -  Known hypersensitivity to the formula components used during the clinical trial;&#xD;
&#xD;
          -  Type 1 diabetes mellitus;&#xD;
&#xD;
          -  Fasting blood glucose &gt; 300 mg/dL;&#xD;
&#xD;
          -  Risk factors for volume depletion;&#xD;
&#xD;
          -  Impaired renal function and end-stage renal disease;&#xD;
&#xD;
          -  Participants with current treatment and continued for more than 15 days with systemic&#xD;
             steroids at the time of informed consent;&#xD;
&#xD;
          -  Impaired hepatic function;&#xD;
&#xD;
          -  Medical history of pancreatic diseases that may suggest insulin deficiency;&#xD;
&#xD;
          -  Bariatric surgery in the last two years and/ or other gastrointestinal surgeries that&#xD;
             can cause chronic malabsorption syndrome;&#xD;
&#xD;
          -  Condition that, in the investigator's judgment, may favor clinically significant&#xD;
             changes in CPK levels;&#xD;
&#xD;
          -  Medical history of acute coronary syndrome, stroke, unstable congestive heart failure,&#xD;
             or respiratory failure within 6 months prior to informed consent;&#xD;
&#xD;
          -  Current medical history of cancer and/ or cancer treatment in the last 5 years;&#xD;
&#xD;
          -  Medical history of metabolic acidosis and/or using drugs that may cause lactic&#xD;
             acidosis;&#xD;
&#xD;
          -  Medical history of blood dyscrasia or any other hemolytic disorders;&#xD;
&#xD;
          -  Participants using sulfonylureas and/or insulin therapy;&#xD;
&#xD;
          -  Treatment with anti-obesity drugs for less than 2 months or with dose change in the&#xD;
             last 2 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Monalisa FB Oliveira, MD</last_name>
    <phone>+551938879851</phone>
    <email>pesquisa.clinica@ncfarma.com.br</email>
  </overall_contact>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 11, 2020</study_first_submitted>
  <study_first_submitted_qc>December 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>December 11, 2020</last_update_submitted>
  <last_update_submitted_qc>December 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

